- Home
- OPFI vs XOMA Comparison
OPFI vs XOMA Comparison
Compare OPFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- XOMA
- Stock Information
- Founded
- OPFI 2009
- XOMA 1981
- Country
- OPFI United States
- XOMA United States
- Employees
- OPFI N/A
- XOMA N/A
- Industry
- OPFI Finance: Consumer Services
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- XOMA Health Care
- Exchange
- OPFI Nasdaq
- XOMA Nasdaq
- Market Cap
- OPFI 300.3M
- XOMA 330.2M
- IPO Year
- OPFI N/A
- XOMA N/A
- Fundamental
- Price
- OPFI $10.46
- XOMA $35.24
- Analyst Decision
- OPFI Buy
- XOMA Strong Buy
- Analyst Count
- OPFI 2
- XOMA 2
- Target Price
- OPFI $11.75
- XOMA $69.50
- AVG Volume (30 Days)
- OPFI 1.1M
- XOMA 61.1K
- Earning Date
- OPFI 11-06-2025
- XOMA 11-06-2025
- Dividend Yield
- OPFI 9.56%
- XOMA N/A
- EPS Growth
- OPFI N/A
- XOMA N/A
- EPS
- OPFI N/A
- XOMA N/A
- Revenue
- OPFI $320,831,000.00
- XOMA $44,952,000.00
- Revenue This Year
- OPFI $116.69
- XOMA $82.30
- Revenue Next Year
- OPFI $9.90
- XOMA $12.59
- P/E Ratio
- OPFI N/A
- XOMA N/A
- Revenue Growth
- OPFI 31.26
- XOMA 194.98
- 52 Week Low
- OPFI $3.93
- XOMA $18.35
- 52 Week High
- OPFI $17.73
- XOMA $36.32
- Technical
- Relative Strength Index (RSI)
- OPFI 48.70
- XOMA 70.27
- Support Level
- OPFI $9.81
- XOMA $32.01
- Resistance Level
- OPFI $10.29
- XOMA $34.60
- Average True Range (ATR)
- OPFI 0.45
- XOMA 1.82
- MACD
- OPFI 0.11
- XOMA 0.12
- Stochastic Oscillator
- OPFI 79.17
- XOMA 81.28
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.